199 related articles for article (PubMed ID: 26671072)
1. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.
Chen Y; Sadow PM; Suh H; Lee KE; Choi JY; Suh YJ; Wang TS; Lubitz CC
Thyroid; 2016 Feb; 26(2):248-55. PubMed ID: 26671072
[TBL] [Abstract][Full Text] [Related]
2. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
3. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
4. BRAF
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma.
Kim KJ; Kim SG; Tan J; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
Eur J Cancer; 2020 Jan; 124():161-169. PubMed ID: 31790974
[TBL] [Abstract][Full Text] [Related]
6. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
8. Association of BRAF
Attia AS; Hussein M; Issa PP; Elnahla A; Farhoud A; Magazine BM; Youssef MR; Aboueisha M; Shama M; Toraih E; Kandil E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555268
[TBL] [Abstract][Full Text] [Related]
9. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
Ma YJ; Deng XL; Li HQ
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
[TBL] [Abstract][Full Text] [Related]
10. Morphological features predictive for BRAF(V600E) mutation in papillary thyroid microcarcinomas.
Nechifor-Boilă AC; Szász EA; Descotes F; Berger N; Zahan AE; Loghin A; Ceteraş DM; Borda A
Rom J Morphol Embryol; 2018; 59(3):747-753. PubMed ID: 30534813
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
Huang Y; Qu S; Zhu G; Wang F; Liu R; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
J Natl Cancer Inst; 2018 Apr; 110(4):362-370. PubMed ID: 29165667
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
13. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
14. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
[TBL] [Abstract][Full Text] [Related]
15. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
Liu C; Chen T; Liu Z
World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.
Prescott JD; Sadow PM; Hodin RA; Le LP; Gaz RD; Randolph GW; Stephen AE; Parangi S; Daniels GH; Lubitz CC
Surgery; 2012 Dec; 152(6):984-90. PubMed ID: 23158172
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.
Pelttari H; Schalin-Jäntti C; Arola J; Löyttyniemi E; Knuutila S; Välimäki MJ
APMIS; 2012 May; 120(5):380-6. PubMed ID: 22515292
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
19. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract][Full Text] [Related]
20. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
